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Numerous germline single nucleotide polymorphisms increase susceptibility to prostate 
cancer, some lying near genes involved in cellular radiation response.    This study 
investigated whether prostate cancer patients with a high genetic risk have increased 
toxicity following radiotherapy.  
Methods 
The study included 1,560 prostate cancer patients from four radiotherapy cohorts: 
RAPPER (n=533), RADIOGEN (n=597), GenePARE (n=290), CCI (n=150). Data from 
genome-wide association studies were imputed with the 1000 Genomes reference panel. 
Individuals were genetically similar with a European ancestry based on principal 
component analysis. Genetic risks were quantified using polygenic risk scores.  
Regression models tested associations between risk scores and 2-year toxicity (overall, 
urinary frequency, decreased stream, rectal bleeding). Results were combined across 
studies using standard inverse-variance fixed effects meta-analysis methods. 
Results 
75 variants were genotyped/ imputed successfully. Neither non-weighted nor weighted 
polygenic risk scores were associated with late radiation toxicity in individual studies 
(p>0.11) or after meta-analysis (p>0.24). No individual variant was associated with 2-
year toxicity.  
Conclusion 
Patients with a high polygenic susceptibility for prostate cancer have no increased risk 
for developing late radiotherapy toxicity. . These findings suggest that patients with a 
genetic pre-disposition for prostate cancer, inferred by common variants, can be safely 
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Prostate carcinoma accounts for a quarter of cancer diagnoses in men in the UK  and is the 
fourth most common cancer worldwide with an estimated 1.1 million men diagnosed in 2012 
(Globocan, 2012, UK, 2014).  It is estimated that approximately a third of patients with 
localised or locally advanced prostate cancer undergo external beam radiotherapy (RT) with 
curative intent (Foroudi et al., 2003). The use of RT in combination with androgen-
deprivation prolongs survival (Martin and D'Amico, 2014), and has contributed to the 
increase in 5-year survival rate from 30% in the 1970s to 80% in 2009 (UK, 2014). Due to 
increased cure rates, cancer survivorship and late treatment toxicity have become 
increasingly important issues in healthcare provision (England, 2013).  
Late toxicity following irradiation for prostate cancer includes damage to the bladder, bowel 
and erectile function (Peeters et al., 2005). The median rates of late gastrointestinal (GI) and 
genitourinary (GU) toxicity are reported to be 15% and 17% respectively (Ohri et al., 2012). 
The rates of severe GI and GU toxicity are reported to be 2% and 3% respectively (Ohri et 
al., 2012). There is now supporting evidence  new techniques such as Intensity Modulated 
Radiotherapy (IMRT) reduce rates of long term GI and GU side effects compared to 3-D 
conformal RT, even with dose escalation (Dolezel et al., 2015, Wilkins et al., 2015). Despite 
these advances approximately one in five patients will experience some degree of late 
radiation toxicity (Dolezel et al., 2015).  
Studies are attempting to identify the genetic variants that increase an individual’s risk of 
radiation toxicity (Fachal et al., 2014, Barnett et al., 2014, Kerns et al., 2013b). This work has 
highlighted the need to increase the statistical power to identify individual common variants 
with small effects (Barnett et al., 2012a). To address this need the Radiogenomics 
Consortium (RGC) was established in 2009 to facilitate large scale collaborative research 
with sufficient power to detect genetic variants that predict a patient’s risk of radiation toxicity 
(West et al., 2010).  RGC groups have undertaken genome wide association studies 
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(GWAS) and are starting to identify replicated variants that increase a prostate cancer 
patient’s risk of toxicity (Fachal et al., 2014).  
In the cancer pre-disposition field, GWAS have identified 76 common single nucleotide 
polymorphisms (SNPs) associated with prostate cancer susceptibility (Eeles et al., 2013a). 
While the biologic role of these SNPs in the development of prostate cancer is an area of on-
going investigation, their proximity to genes which are involved in DNA repair processes 
suggests that disruption of DNA damage response and repair mechanisms may have a key 
role (Hazelett et al., 2014, Eeles et al., 2013a). If a patient has an inherent compromised 
ability to repair DNA damage, they may be predisposed to both prostate cancer and toxicity 
following RT, as the same DNA repair pathways play a central role in cellular response to 
radiation. Also, recent epidemiological evidence suggests that radiation exposure increases 
the risk of developing prostate cancer (Schmitz-Feuerhake and Pflugbeil, 2011, Kondo et al., 
2013, Myles et al., 2008). Therefore, the hypothesis underlying this study was that common 
genetic variants involved in cancer pre-disposition may have roles in both tumour formation 
and in the response of normal tissues to radiation-induced DNA damage.  The aim of this 
study was to investigate the association between prostate cancer germline risk SNPs and 




This prospective study involved four prostate cancer radiotherapy cohorts: RAPPER 
(N=533), RADIOGEN (N=597), GenePARE (N=290) and CCI (N=150).  Informed consent 
was obtained from all patients. RAPPER was approved by the Cambridge South Research 
Ethics Committee (05/Q0108/365). RADIOGEN was approved by the Galician Ethical 
Committee. Gene-PARE was approved by the Mount Sinai Medical Center Institutional 
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Review Board. The CCI study was approved by the Health Research Ethics Board of Alberta 
(Cancer).  
The UK RAPPER study (UKCRN1471) recruited patients who received neoadjuvant 
androgen suppression and external beam radiotherapy (EBRT) from two clinical trials RT01 
(ISRCTN47772397) and CHHiP (ISRCTN97182923). A full description of the cohort is 
available elsewhere (Barnett et al., 2014). The RTO1 study was a randomised dose 
escalation study using 3D conformal radiotherapy comparing 64 Gy and 74 Gy in the 
treatment of localised prostate cancer (Dearnaley et al., 2014). The CHHiP study 
randomised between standard (74 Gy in 37 fractions) and hypofractionated (60 Gy in 20 
fractions or 57 Gy in 19 fractions) intensity modulated radiotherapy (IMRT) (Dearnaley et al., 
2012).  
RADIOGEN comprised patients who received 3D conformal radical or post-prostatectomy 
EBRT at the Clinical University Hospital of Santiago de Compostela, Spain. 473 patients had 
adjuvant hormone therapy. Patients received radical EBRT using doses of between 70 Gy – 
76 Gy in 2 Gy per fraction. The adjuvant EBRT doses used were 60 Gy – 66 Gy in 2 Gy per 
fraction. A full description of the cohort can be found elsewhere (Fachal et al., 2012).  
GenePARE patients received brachytherapy with/without EBRT at the Mount Sinai Hospital, 
New York.  Of the approximately 800 patients included in the initial Gene-PARE study, 290 
individuals of European ancestry had high quality genome-wide SNP data available and 
were included in the present study. 147 of these received adjuvant hormone therapy. 125I 
(160 Gy; TG-43) was used in patients undergoing brachytherapy alone and 103Pd (100 Gy) in 
patients also receiving EBRT. The EBRT regimen was delivered using 3D conformal 
technique using 24 Gy - 50 Gy. EBRT alone was delivered using IMRT using 66.6 Gy – 81 
Gy, and further full details can be found elsewhere (Kerns et al., 2013a).  
The CCI cohort recruited patients from the Cross Cancer Institute in Edmonton and the Tom 
Baker Cancer Centre in Alberta, Canada. Patients underwent EBRT using a 
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hypofractionated (68 Gy in 25 fractions or 55 Gy in 16 fractions) or conventional (72 Gy – 82 
Gy delivered in 2 Gy per fraction) schedule. Approximately 50% of patients received 
androgen suppression. Further treatment details can be found elsewhere (Kerns et al., 
2013b).  
Assessment of Late Radiotherapy Toxicity 
Late toxicity data were collected prospectively and assessed using standardised scoring 
systems (Supplementary Table 1).  Data collected at 2 years were used as in other RGC 
studies (Andreassen et al., 2012, Kerns et al., 2013b, Dearnaley et al., 2012). For rectal 
bleeding in GenePARE, a 1-5 year window was allowed, because the scoring system 
assigns grades based on whether rectal bleeding occurs as a single incident or intermittent 
symptoms over time. 
Decreased stream, urinary frequency and rectal bleeding data were harmonized across the 
four cohorts to create comparable endpoints (see Supplementary Table 2). Toxicity 
endpoints were analysed as change from baseline rather than actual recorded grade such 
that the toxicity captured was due to radiotherapy only.  Due to the low number of high grade 
toxicities (≥2) it was only possible to analyse toxicities as grade 0 versus ≥1 (Table 1). Scale-
independent Standardized Total Average Toxicity (STAT) scores were derived, as described 
previously  (Barnett et al., 2012b), from a range of individual toxicity endpoints to provide an 
overall measure of two-year toxicity that was comparable across the four cohorts.    
Genotyping, Quality Control and Imputation 
Samples were genotyped as part of previously completed GWAS (Kerns et al., 2013b, 
Fachal et al., 2014, Barnett et al., 2014).  Standard quality control procedures were applied 
to remove variants that were missing in >5% of samples, had a minor allele frequency (MAF) 
<1%, or displayed genotype frequencies deviating from those expected under Hardy-
Weinberg equilibrium (p-value<10-6).  Samples that had >3% of all variants missing were 
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removed.  Allele frequencies are known to vary by ancestral background, so principle 
components analysis (PCA) was used to identify and exclude individuals with non-European 
ancestry in order to avoid false positive associations arising from population substructure 
because of the small number of participants with other ethnicities.  Comparable sets of 
variants were produced through imputation using SHAPEIT (Delaneau et al., 2012) and 
IMPUTE2  (Howie et al., 2011) with the 1000 Genomes Phase I reference panel (Abecasis 
et al., 2010).  Supplementary Table 3 lists the 76 known prostate cancer susceptibility SNPs.  
Genotype dosages for the prostate cancer risk alleles were extracted from the imputed data.  
 Statistical Analysis  
Polygenic risk scores were created to quantify the patients’ genetic risk of prostate cancer.  
For each patient, genotype dosages for the prostate cancer risk-increasing alleles were 
calculated and then summed across all the variants.  Two types of risk score were 
calculated: 
Non-weighted, for patient 𝑖:   𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒𝑖 =  ∑ 𝐺𝑖𝑗
𝑗
1    
Weighted, for patient 𝑖:  𝑤𝑒𝑖𝑔ℎ𝑡𝑒𝑑 𝑟𝑖𝑠𝑘 𝑠𝑐𝑜𝑟𝑒𝑖 =  ∑ 𝛽𝑗𝐺𝑖𝑗
𝑗
1  
where  𝑗 = variants 1..76 
 𝛽𝑗 = the per-allele log-odds ratio for risk of prostate cancer associated with variant 𝑗 
𝐺 = risk allele dosage 
The log-odds ratios used to weight the risk score were taken from the review paper by Eeles 
et al (Eeles et al., 2013a).   
Within each cohort, logistic regression was used to test the association between each 
individual toxicity endpoint and polygenic risk score, adjusted for important non-genetic 
factors identified by QUANTEC (Bentzen et al., 2010). Total biologically effective dose (BED) 
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was calculated for individuals in all four studies as a measure of radiation dose exposure 
using an α/β=3. Other non-genetic risk factors included were age at treatment, diabetes 
(rectal bleeding only), rectal volume (rectal bleeding only), transurethral resection of the 
prostate (TURP) prior to radiotherapy (urinary endpoints only), and baseline toxicity (Table 
1).  Linear regression was used to test the association between STAT score and polygenic 
risk score, adjusted for all the non-genetic factors above.  Logistic and linear regression was 
also used to test each genetic variant individually.  Regression coefficients and their 
standard errors were then meta-analysed using standard inverse-variance weighted fixed 
effects meta-analysis methods.     
Power Calculations 
This study was well powered to detect significant associations between prostate cancer 
polygenic risk scores and common radiotherapy toxicity endpoints.  Assuming a moderate 
difference of 0.34 in mean polygenic risk score between prostate cancer patients who 
experience toxicity and those who do not, with a significance level of 𝛼=0.05, the power to 
detect an association between toxicity (grade≥1) and polygenic risk score would be 99% for 
a toxicity endpoint with 15% prevalence (grade≥1) and 96% for a toxicity endpoint with 6% 
prevalence (grade≥1).    This difference in mean risk would be equivalent to a relative risk of 
toxicity of 1.4 for the subset of patients with a higher mean polygenic risk of prostate cancer. 
Results  
The distributions of patient characteristics, toxicity endpoints and STAT scores are 
summarised in Table 1. Of the 76 germline prostate cancer risk SNPs, 75 were genotyped or 
imputed successfully (R2>0.3) (Table 2).  Histograms of the polygenic risk scores show an 
approximate normal distribution within each cohort (Figure 1). Brachytherapy slightly 
increases urinary toxicity compared with EBRT alone, which explains the higher urinary 
toxicity in Gene-PARE (Sutani et al., 2015).  
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The results of the association analyses are shown in Table 3 and Supplementary Tables 4-7. 
Neither the non-weighted nor the weighted polygenic risk score was associated with any late 
radiotherapy individual toxicity endpoints or STAT score in any of the individual studies or on 
meta-analysis (meta-analysis p>0.35 and p>0.33 for non-weighted and weighted scores 
respectively; Table 3). None of the individual SNPs were associated with late radiation 
toxicity at 2 years at the pre-specified significance level of p-value<5x10-4 in any of the 
individual studies or on meta-analysis (Supplementary Tables 4-7).  There was no statistical 






This study found no evidence that prostate cancer patients with a high polygenic risk score 
for susceptibility to the disease have an increased risk of developing late toxicity following 
RT. The study was well powered to detect an association between prostate cancer polygenic 
risk and radiotherapy toxicity endpoints with a prevalence ≥6% and a moderate effect of 
RR=1.4. There was also no evidence for individual SNPs to be associated with risk of 
toxicity, although the study was not sufficiently powered to detect associations with individual 
SNPs that are each likely to carry a very small risk for radiotherapy toxicity.  Rare, highly 
penetrant variants like BRCA1, BRCA2 and HOXB13 were not included in this analysis as 
they require sequencing in a much larger number of patients and different statistical analysis 
methods.  
The biggest non-genetic determinant of radiotherapy toxicity is known to be dose (Kerns et 
al., 2015).   In this study we calculated biologically effective dose [BED] to allow comparison 
across cohorts receiving external beam therapy only (RAPPER, RADIOGEN and CCI) and 
those receiving brachytherapy as well (Gene-PARE).  Other important non-genetic factors 
such as age and co-morbidities were also adjusted for.  Tests for heterogeneity in these 
factors across the cohorts were highly significant, suggesting that the cohorts are not 
homogeneous.  However, none of the meta-analysis p-values for heterogeneity were 
statistically significant.  Thus, although the heterogeneity of the cohorts may have reduced 
the power of the meta-analysis, it is unlikely to have biased the results for the SNPs. 
The prostate cancer risk SNPs are mostly located in intronic regions and the functional 
target genes through which they increase prostate cancer risk are not known.  However, 
some SNPs associated with prostate cancer risk reside near genes that may influence the 
DNA repair process. The SNP rs817826, identified in a Han Chinese population, lies in an 
intergenic region between RAD23B and KLF4 (Xu et al., 2012). RAD23B is a key protein 
involved in the nucleotide excision repair pathway which functions to repair single strand 
13 
 
DNA breaks from ionising radiation (Clement et al., 2010). Defects in this pathway have 
been associated with photosensitive conditions such as xeroderma pigmentosa (XP) and 
increase the likelihood of double strand breaks and late radiation toxicity (Feltes and 
Bonatto, 2015).  Another SNP, rs1938781, found on chromosome 11q12 lies very close to 
FAM111A and FAM111B (Akamatsu et al., 2012). Mutations in FAM111B have been 
associated with the development of hereditary fibrosing poililoderma with pulmonary fibrosis, 
tendon contracture, and myopathy (Mercier et al., 2013). The underlying mechanism in 
which FAM111B causes the above abnormalities is not known. One of the most interesting 
SNPs, rs7141529 on chromosome 14q24, is an intronic SNP in the DNA repair gene 
RAD51B (Eeles et al., 2013c). Though the functional effect of this SNP is unknown, RAD51B 
is involved in homologous recombination repair induced by double strand DNA breaks such 
as those caused by RT. SNPs in the TERT locus of 5p15 have been shown to affect prostate 
cancer risk by interfering with TERT expression (Amin Al Olama et al., 2013). The TERT 
gene functions by adding telomere repeat sequences at the end of chromosomes, which 
prevent cells undergoing telomere dependent senescence (Kote-Jarai et al., 2013). A 
number of proteins have been identified that are involved in telomere maintenance as well 
as being involved in repair of DNA double strand breaks by homologous recombination 
(Huda et al., 2009). Another SNP that has an association with aggressive prostate cancer is 
rs4245739 which is located in the 3’ untranslated (UTR) of MDM4 on chromosome 1q32 
(Eeles et al., 2013c).  When functioning normally MDM4 is a critical negative regulator of the 
tumour suppressor gene TP53. MDM4 is frequently overexpressed in many cancers that 
have wild type TP53 (Wynendaele et al., 2010). TP53 is involved in DNA repair (Merino and 
Malkin, 2014). 
Studies investigating genetic variation in relation to risk of radiotherapy toxicity focused 
initially on ATM, because individuals with homozygote mutations are extremely sensitive to 
radiation. The first SNP studies were reported at the start of twenty-first century, and the 
most widely studied genes encoded proteins associated with DNA repair (e.g. ATM), the 
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development of fibrosis (e.g. TGFB1) and scavenging of reactive oxygen species (e.g. 
SOD2). Although significant associations were reported, replication was often unsuccessful 
(Andreassen et al 2006, Barnett et al 2012 Lancet Oncol). Since the establishment of the 
RGC, replicated associations have been found in both large candidate gene (Talbot et al 
2012 BJC; Siebold et al 2015) and genome wide association (Fachal et al 2014) studies. It is 
interesting to note that the SNPs being identified through GWAS fall in or near genes 
associated with the function of the tissue irradiated (Kerns et al., 2015, Kerns et al., 2014a, 
Kerns et al., 2014b, Rosenstein et al., 2014,)Fachal et al 2014). Although DNA damage 
response gene products have a clear role in cancer eradication, other pathways are clearly 
important in the  pathogenesis of late radiotherapy toxicity (Bentzen, 2006).  
The study reported here had a number of limitations. First, the findings are limited to prostate 
cancer risk conferred by common variants only – many thousands of participants will need to 
be studied to assess a role for rare variants. Second, our analysis was limited to men who 
were genetically of European ancestry and therefore the conclusions may not be 
generalisable to men of other ethnicities. Third, many genes that predispose to prostate 
cancer have not yet been identified. Fourth, there are likely to be un-recorded toxicities in 
patients because under-reporting is a known issue of data collection in radiotherapy studies 
(Bentzen et al., 2010). For example, it was not possible to analyse sexual dysfunction as no 
data were available for two of the cohorts.  
Only 33% of common germline variants that predict the familial risk of developing prostate 
cancer have so far been discovered (Eeles et al., 2014). The top 1% of the risk distribution 
have a 4.7 times increased risk of developing prostate cancer than the average population 
being profiled (Eeles et al., 2013c). The National Institute of Health funded GAME-ON 
initiative is a cross cancer genotyping project which will include 100,000 prostate cancer 
patient samples on a genotyping array of 500,000 SNPs. Through this expanded genotyping 
effort, additional risk SNPs for prostate cancer susceptibility are expected to be identified. 
Around 5,000 samples from the RGC are included in the OncoArray genotyping initiative, 
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and can be used to test associations between SNPs and radiotherapy toxicity in a future 
larger study with more SNPs covering a larger percentage of the familial risk. The larger 
sample size should allow for better testing of individual SNPs.  
In summary, this work showed that there is no association between genetic susceptibility to 
developing prostate cancer and  the development of late radiation toxicity.. The implication of 
this finding is that standard RT for prostate cancer can be given to patients with an increased 
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Age      
Mean (SD) 67.2 (5.7) 71.0 (6.5) 64.0 (7.5) 66.7 (7.4) p<0.00005 
      
Diabetes      
Yes n(%) 39 (7.3) 144 (24.1) 16 (5.5) 24 (16.0) 
p<0.00005 No n(%) 493 (92.5) 453 (75.9) 274 (94.5) 122 (81.3) 
Missing n(%) 1 (0.2) 0 0 4 (2.7) 
      
Prior TURP1      
Yes n(%) 56 (10.5) 45 (7.5) 6 (2.1) 6 (4.0)  
No n(%) 472 ( (88.6) 552 (92.5) 284 (97.9) 144 (96.0) p=0.0002 
Missing n(%) 5 (0.9) 0 0 0  
      
BED2      
Mean (SD) 120.5 (6.2) 120.5 (5.6) 191.9 (22.4) 125.5 (6.2) p<0.00005 
      
STAT 2 years3      
Mean (SD) -0.01 (0.5) 0.02 (0.8) 0.12 (0.7) -0.01 (0.7) 0.06 
      
Decreased 
Stream 
    
 
Grade 0 n(%) 483 (90.6) 472 (79.1) 189 (65.2) NA 
p<0.00005 Grade ≥1 n(%) 29 (5.5) 6 (1.0) 66 (22.7) NA 
Missing n(%) 21 (3.9) 119 (19.9) 35 (12.1) NA 






Grade 0 n(%) 482 (90.5) 423 (70.9) 179 (61.7) 120 (80) 
p<0.00005 Grade ≥1 n(%) 45 (8.4) 54 (9.0) 76 (26.2) 30 (20) 
Missing n(%) 6 (1.1) 120 (20.1) 35 (12.1) 0 






Grade 0 n(%) 446 (83.7) 522 (87.4) 208 (71.7) 110 (73.3)  
Grade ≥1 n(%) 81 (15.2) 74 (12.4) 82 (28.3) 40 (26.7) p<0.00005 
Missing n(%) 6 (1.1) 1 (0.2) 0 0  
1TURP trans-urethral resection of the prostate 
2BED biologically effective dose 
3STAT standardized total average toxicity 




Table 2: SNPs associated with prostate cancer 
SNP Chromosome Position 
Alleles 
major/minor 
RAPPER RADIOGEN GenePARE CCI 
MAF R2 e MAF R2 e MAF R2 e MAF R2 e 
rs1218582 1 154834183 A/G 0.45 0.94 0.50 0.87 0.43 0.96 0.48 0.96 
rs4245739 1 204518842 A/C 0.24 0.99 0.30 0.99 0.28 1 0.23 1 
rs11902236 2 10117868 G/A 0.27 0.93 0.29 1 0.27 0.91 0.28 1 
rs13385191 2 20888265 G/Ad 0.25 0.99 0.24 1 0.27 1 0.26 1 
rs1465618 2 43553949 G/A 0.22 0.98 0.26 0.98 0.23 0.98 0.22 1 
rs721048 2 63131731 G/A 0.22 1 0.22 1 0.18 0.94 0.17 0.93 
rs10187424 2 85794297 A/G 0.37 1 0.44 0.99 0.42 0.99 0.42 1 
rs12621278 2 173311553 A/G 0.04 0.97 0.04 1 - - - - 
rs2292884 2 238443226 A/G 0.28 1 0.23 0.97 0.24 0.99 0.22 0.99 
rs3771570 2 242382864 G/A 0.18 0.99 0.16 0.96 0.14 1 0.15 1 
rs2660753 3 87110674 C/T 0.11 1 0.16 1 0.19 0.96 0.08 0.98 
rs2055109 3 87467332 C/Td 0.26 1 0.28 0.99 0.24 0.86 0.22 0.99 
rs7611694 3 113275624 A/C 0.41 1 0.37 0.98 0.36 1 0.39 1 
rs10934853 3 128038373 C/A 0.29 0.98 0.29 0.94 0.32 1 0.34 1 
rs6763931 3 141102833 C/T 0.45 0.98 0.39 1 0.40 0.96 0.39 1 
rs10936632 3 170130102 A/C 0.49 0.94 0.45 0.95 0.46 0.94 0.47 0.95 
rs1894292 4 74349158 G/A 0.47 0.86 0.47 1 0.40 0.91 0.44 1 
rs12500426 4 95514609 C/A 0.48 0.96 0.48 0.98 0.49 0.98 0.49 0.99 
rs17021918 4 95562877 C/T 0.31 0.99 0.31 0.99 0.35 1 0.37 1 
rs7679673 4 106061534 C/A 0.34 1 0.38 0.99 0.49 0.99 0.38 1 
rs2242652 5 1280028 G/A 0.19 0.91 0.15 0.45 0.22 0.62 0.19 0.62 
rs12653946 5 1895829 C/T 0.45 1 0.46 0.58 0.48 0.90 0.44 0.90 
rs2121875 5 44365545 T/G 0.35 1 0.37 1 0.41 0.99 0.34 1 
rs6869841 5 172939426 G/A 0.23 0.98 0.21 0.99 0.24 0.99 0.23 0.99 
rs130067a 6 31118511 T/G 0.21 1 0.19 1 NA NA NA NA 
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SNP Chromosome Position 
Alleles 
major/minor 
RAPPER RADIOGEN GenePARE CCI 
MAF R2 e MAF R2 e MAF R2 e MAF R2 e 
rs3096702b 6 32192331 G/A 0.42 0.97 0.28 1 NA NA NA NA 
rs1983891 6 41536427 C/T 0.29 0.95 0.35 0.98 0.31 1 0.31 1 
rs2273669 6 109285189 A/G 0.15 0.99 0.16 0.97 0.12 0.97 0.14 0.99 
rs339331 6 117210052 T/Cd 0.27 0.97 0.25 1 0.19 1 0.32 1 
rs1933488 6 153441079 A/G 0.38 0.99 0.41 1 0.44 1 0.41 1 
rs9364554 6 160833664 C/T 0.33 0.99 0.25 1 0.25 1 0.29 1 
rs12155172 7 20994491 G/A 0.22 0.82 0.21 1 0.21 0.97 0.22 0.97 
rs10486567 7 27976563 G/Ad 0.19 0.97 0.20 1 0.25 0.99 0.21 0.98 
rs6465657 7 97816327 T/C 0.49 1 0.47 1 0.41 1 0.49 1 
rs2928679 8 23438975 C/T 0.48 1 0.45 0.99 0.49 0.97 0.46 1 
rs1512268 8 23526463 G/A 0.45 0.99 0.50 0.98 0.49 0.99 0.42 1 
rs11135910 8 25892142 G/A 0.2 0.93 0.15 1 0.16 0.97 0.18 0.99 
rs12543663 8 127924659 A/C 0.35 0.94 0.26 0.97 0.31 0.94 0.33 0.94 
rs10086908 8 128011937 T/C 0.27 1 0.31 1 0.26 1 0.26 0.99 
rs16901979 8 128124916 C/A 0.05 0.99 0.05 1 0.05 1 0.05 1 
rs620861 8 128335673 C/T 0.34 1 0.36 0.99 0.36 0.99 0.31 0.99 
rs6983267 8 128413305 G/Td 0.43 0.95 0.40 1 0.48 0.98 0.45 1 
rs1447295 8 128485038 C/A 0.14 0.97 0.07 1 0.09 0.99 0.10 0.99 
rs817826 9 110156300 T/C 0.17 0.64 0.17 0.94 0.21 1 0.12 1 
rs1571801 9 124427373 C/A 0.28 0.76 0.23 1 0.22 1 0.32 1 
rs10993994 10 51549496 C/T 0.46 0.79 0.43 1 0.47 0.92 0.43 0.92 
rs3850699 10 104414221 A/G 0.28 0.99 0.28 0.96 0.29 0.97 0.26 0.97 
rs2252004 10 122844709  G/Td 0.09 0.99 0.09 0.99 0.11 1 0.09 1 
rs4962416 10 126696872 T/C 0.28 0.93 0.31 1 0.31 0.98 0.24 0.98 
rs7127900 11 2233574 G/A 0.22 0.98 0.23 0.91 0.27 0.59 0.22 0.96 
rs1938781 11 58915110 T/C 0.21 1 0.21 1 0.20 0.99 0.19 1 
rs7931342 11 68994497 G/T 0.46 1 0.41 1 0.36 1 0.41 1 
rs11568818 11 102401661 A/G 0.44 0.89 0.46 0.99 0.42 0.91 0.42 0.93 
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SNP Chromosome Position 
Alleles 
major/minor 
RAPPER RADIOGEN GenePARE CCI 
MAF R2 e MAF R2 e MAF R2 e MAF R2 e 
rs902774 12 53273904 G/A 0.16 0.98 0.14 1 0.17 0.99 0.18 1 
rs1270884 12 114685571 G/A 0.48 0.93 0.49 0.98 0.48 0.98 0.48 1 
rs10875943 12 49676010 T/C 0.32 0.86 0.28 1 0.32 0.93 0.29 0.95 
rs9600079 13 73728139 G/T 0.46 0.86 0.47 1 0.43 0.89 0.46 0.95 
rs8008270 14 53372330 G/A 0.15 1 0.19 0.99 0.19 1 0.16 1 
rs7141529 14 69126744 G/Ad 0.47 1 0.45 1 0.46 0.99 0.49 0.99 
rs4430796 17 36098040 G/A 0.47 0.94 0.49 0.88 0.49 0.90 0.45 0.93 
rs7210100c 17 47436749 A/G - - - - - - - - 
rs11649743 17 36074979 G/Ad 0.2 1 0.19 1 0.15 1 0.16 1 
rs11650494 17 47345186 G/A 0.09 0.99 0.08 0.93 0.13 0.99 0.09 0.99 
rs684232 17 618965 A/G 0.35 0.99 0.33 0.98 0.34 0.98 0.39 0.99 
rs1859962 17 69108753 T/G 0.5 0.99 0.45 1 0.43 1 0.47 1 
rs7241993 18 76773973 G/A 0.28 0.94 0.28 0.91 0.32 0.51 0.32 0.56 
rs8102476 19 38735613 C/Td 0.42 0.99 0.34 0.96 0.38 0.97 0.43 0.97 
rs11672691 19 41985587 A/Gd 0.24 0.87 0.21 0.93 0.23 0.93 0.27 0.93 
rs103294f 19 54797848 T/C 0.23 1 0.20 1 0.22 0.30 - - 
rs2735839 19 51364623 G/A 0.12 1 0.15 1 0.17 0.93 0.16 0.97 
rs2427345 20 61015611 G/A 0.35 0.99 0.35 0.37 0.39 0.91 0.40 0.96 
rs6062509 20 62362563 A/C 0.32 1 0.26 0.99 0.27 0.98 0.28 0.98 
rs5759167 22 43500212 G/T 0.47 1 0.45 0.90 0.46 0.80 0.47 1 
rs2405942 23 9814135 A/G 0.17 1 0.20 0.95 0.21 0.94 0.23 0.93 
rs5919432 23 67021550 A/G 0.14 0.98 0.18 1 0.21 1 0.18 1 
rs5945619 23 51241672 T/C 0.41 0.92 0.44 1 0.38 1 0.33 1 
amerged SNP rs115664826 
bmerged SNP rs114376585 
crs7210100 MAF=0, R2=0, excluded from RAPPER analyses; RADIOGEN R2= 0.005; not imputed in GenePARE or CCI datasets 
dmajor allele is associated with increased risk of prostate cancer 
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eR2 refers to the “imputation info” metric produced by IMPUTE2, which represents the certainty with which the SNP has been imputed and lies 
between 0 (no certainty) and 1 (high certainty; R2=1 for genotyped SNPs). 





Table 3: Polygenic risk score analyses results 
 
RAPPER RADIOGEN GenePARE CCI Meta-analysis 
beta (95% CI) p
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0.49 4.15, 0.25 
Decreased 
stream 











0.91 NA NA 
0.001 
(-0.001, 0.003) 











0.86 NA NA 
0.01 
(-0.01, 0.02) 
0.33 1.84, 0.40 
Urine 
frequency 


































0.42 2.18, 0.54 
Rectal 
bleeding 


































0.90 3.32, 0.34 
1
p-value corresponding to beta estimate 
2
p-value for test of heterogeneity between studies 
3
Standardized total average toxicity 
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Titles and legends to figures 
Figure 1: Histograms showing the approximate normal distributions for the unweighted and 
the weighted polygenic risk scores in A) the RAPPER cohort, B) the RADIOGEN cohort, C) 






Supplementary Table 1: Standardized scoring systems for toxicity data collection  
 
 
Study/trial Toxicity endpoint and scale Grade 





Proctitis  0 = No toxicity 
1 = Minor symptoms requiring no treatment 
2 = Symptoms responding to simple OPD management; lifestyle & PS unaffected 
3 = Distressing symptoms altering lifestyle & PS. Hospitalisation for diagnosis or minor 
surgical intervention may be required 
4 = Major surgical intervention (e.g. laparotomy, colostomy) or prolonged hospitalisation 
 Clinical assessment (RMH) of late 
toxicity  
 
RT01, CHHiP Rectal bleeding  0 = No toxicity 
1 = Occasional (no treatment) 
2 = Moderate (simple OPD treatment) 
3 = Severe (blood transfusion, surgery) 
RT01, CHHiP Nocturnal frequency  0 = 0-1 times 
1 = 2-3 times 
2 = 4-5 times 
3 = 6-8 times 
4 = >8 times 
 Clinical assessment (LENT-SOM) of 
late toxicity 
 
RT01, CHHiP Sphincter control  0 = No toxicity 
1 = Occasional 
2 = Intermittent 
3 = Persistent 
4 = Refractory 
RT01, CHHiP Stool frequency 0 = < 2 per day 
1 = 2-4 per day 
2 = 5-8 per day 
3 = >8 per day 
4 = Uncontrolled diarrhoea 
RT01, CHHiP Urinary frequency 0 = >4 hour intervals 
1 = 3-4 hour intervals 
2 = 2-3 hour intervals 
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Study/trial Toxicity endpoint and scale Grade 
3 = 1-2 hour intervals 
4 = Hourly 
RT01, CHHiP Urine incontinence 0 = No toxicity 
1 = < weekly episodes 
2 = < daily episodes 
3 = <2 pads / undergarments / day 
4 = Refractory 
RT01, CHHiP Decreased stream  0 = No toxicity 
1 = Occasionally weak 
2 = Intermittent 
3 = Persistent but incomplete 
4 = Complete obstruction 
 Clinical assessment (CTCAEv3.0) of 
late toxicity  
0 = None 
1 = Minimal (simple OPD treatment) 
2 = Moderate (simple OPD treatment) 
3 = Severe (blood transfusion, surgery) 
RADIOGEN Rectal bleeding 
RADIOGEN Proctitis 0 = No toxicity 
1 = Rectal discomfort, intervention not indicated 
2 = Symptoms not interfering with ADL; medical intervention indicated  
3 = Stool incontinence or other symptoms interfering with ADL; operative intervention 
indicated 
4 = Life-threatening consequences (e.g., perforation) 
RADIOGEN Sphincter control 0 = No toxicity 
1 = Occasional use of pads required 
2 = Daily use of pads required 
3 = Interfering with ADL; operative intervention indicated 
4 = Permanent bowel diversion indicated 
RADIOGEN Diarrhoea 0 = No toxicity 
1 = Increase of <4 stools per day over baseline; mild increase in stoma output compared 
to baseline 
2 = Increase of 4 – 6 stools per day over baseline; IV fluids indicated <24hrs; moderate 
increase in stoma output compared to baseline; not interfering with ADL 
3 = Increase of ≥7 stools per day over baseline; incontinence; IV fluids ≥24 hrs; 
hospitalization; severe increase in stoma output compared to baseline; interfering with 
ADL 
4 = Uncontrolled diarrhea 
RADIOGEN Urinary frequency 0 = No toxicity 
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Study/trial Toxicity endpoint and scale Grade 
1 = Increase in frequency or nocturia up to 2 x normal; enuresis 
2 = Increase >2 x normal but <hourly 
3 = ≥1 x/hr; urgency; catheter indicated 
RADIOGEN Nocturnal frequency 0 = No toxicity 
1 = Increase in frequency or nocturia up to 2 x normal; enuresis 
2 = Increase >2 x normal but <hourly 
3 = ≥1 x/hr; urgency; catheter indicated 
RADIOGEN Urine incontinence 0 = No toxicity 
1 = Occasional (e.g., with coughing, sneezing, etc.), pads not indicated 
2 = Spontaneous, pads indicated 
3 = Interfering with ADL; intervention indicated (e.g., clamp, collagen injections) 
4 = Operative intervention indicated (e.g., cystectomy or permanent urinary diversion) 
RADIOGEN Decreased stream 0 = No toxicity 
1 = Hesitancy or dribbling, no significant residual urine; retention occurring during the 
immediate postoperative period 
2 = Hesitancy requiring medication; or operative bladder atony requiring indwelling 
catheter beyond immediate postoperative period but for <6 weeks 
3 = More than daily catheterization indicated; urological intervention indicated (e.g., 
TURP, suprapubic tube, urethrotomy) 
4 = Life-threatening consequences; organ failure (e.g., bladder rupture); operative 
intervention requiring organ resection indicated 
 Patient-reported outcome (IPSS)  
GenePARE Nocturnal frequency In the last month or so, how many times did you most typically get up to urinate from the 
time you went to bed at night until the time you get up in the morning? 
0 = None 
1 = 1 time 
2 = 2 times 
3 = 3 times 
4 = 4 times 
5 = 5 times or more 
GenePARE Decreased stream In the last month or so, how often have you had to push or strain to urinate? 
0 = Not at all 
1 = Less than 1 time in 5 
2 = Less than ½ the time 
3 = About ½ the time 
4 = More than ½ the time 
5 = Almost always 
36 
 
Study/trial Toxicity endpoint and scale Grade 
GenePARE Urinary frequency In the last month or so, how often have you had to urinate again less than 2 hours after 
you have urinated? 
1 = Less than 1 time in 5 
2 = Less than ½ the time 
3 = About ½ the time 
4 = More than ½ the time 




Supplementary Table 2:  Harmonization of toxicity scoring systems across studies. 
Toxicity 
endpoint 



















2 2 4 2 
3 













3 2 4 2 





























OR* (95% CI) 
Nearby genes Reference 




(Amin Al Olama 
et al.) 





(Amin Al Olama 
et al.) 




(Eeles et al., 
2013b) 





et al., 2008) 




(Al Olama et 
al., 2009) 




(Takata et al., 
2010) 




(Amin Al Olama 
et al.) 




(Al Olama et 
al., 2009) 




(Eeles et al., 
2013b) 




(Amin Al Olama 
et al.) 










(Eeles et al., 
2008) 




(Amin Al Olama 
et al.) 





et al., 2009) 




(Eeles et al., 
2013b) 




(Eeles et al., 
2013b) 




(Amin Al Olama 
et al.) 




(Al Olama et 
al., 2009) 













OR* (95% CI) 
Nearby genes Reference 
1.12) al., 2009) 




(Al Olama et 
al., 2009) 




(Eeles et al., 
2013b) 




(Eeles et al., 
2013b) 




(Takata et al., 
2010) 





(Amin Al Olama 
et al.) 




(Eeles et al., 
2013b) 




(Takata et al., 
2010) 




(Amin Al Olama 
et al.) 





(Amin Al Olama 
et al.) 




(Takata et al., 
2010) 




(Eeles et al., 
2008) 




(Amin Al Olama 
et al.) 




(Thomas et al., 
2008) 




(Amin Al Olama 
et al.) 




(Eeles et al., 
2008) 




(Al Olama et 
al., 2009) 




(Al Olama et 
al., 2009) 




(Amin Al Olama 
et al., 2015) 
8q24 rs1447295 C A 0.13 1.62 (NR) None 
(Amundadottir 













OR* (95% CI) 
Nearby genes Reference 




(Yeager et al., 
2007) 





et al., 2007a) 




(Al Olama et 
al., 2009) 




(Al Olama et 
al., 2009) 




(Al Olama et 
al., 2009) 




(Amin Al Olama 
et al., 2013) 




(Duggan et al., 
2007) 




(Eeles et al., 
2008, Thomas 
et al., 2008) 




(Amin Al Olama 
et al.) 




(Thomas et al., 
2008) 










(Al Olama et 
al., 2009) 










(Eeles et al., 
2008, Thomas 
et al., 2008) 




(Amin Al Olama 
et al., 2015) 




(Eeles et al., 
2013b) 




(Eeles et al., 
2013b) 




(Amin Al Olama 
et al., 2015) 


















OR* (95% CI) 
Nearby genes Reference 




(Amin Al Olama 
et al., 2015) 




(Amin Al Olama 
et al., 2015) 





(Amin Al Olama 
et al., 2015) 





et al., 2007b) 




(Al-Shibli et al., 
2008) 




(Eeles et al., 
2013b) 





(Amin Al Olama 
et al., 2015) 





et al., 2007b) 




(Amin Al Olama 
et al., 2015) 




(Eeles et al., 
2008) 





et al., 2009) 




(Amin Al Olama 
et al., 2013) 




(Amin Al Olama 
et al., 2013) 





(Amin Al Olama 
et al., 2015) 




(Amin Al Olama 
et al., 2015) 




(Al Olama et 
al., 2009) 





et al., 2008, 
Eeles et al., 
2008) 




(Amin Al Olama 
et al., 2015) 








*Data taken from the original publications  









RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p p-het
1
 
rs1218582 G 0.06 (0.03) 0.08 -0.06 (0.05) 0.22 -0.10 (0.07) 0.19 -0.17 (0.09) 0.05 -0.01 (0.03) 0.70 0.02 
rs4245739 A -0.05 (0.04) 0.24 -0.06 (0.05) 0.23 -0.07 (0.07) 0.33 -0.05 (0.10) 0.62 -0.05 (0.03) 0.05 0.99 
rs11902236 A 0.03 (0.04) 0.50 -0.02 (0.05) 0.70 -0.06 (0.07) 0.36 -0.09 (0.10) 0.39 -0.01 (0.03) 0.81 0.59 
rs13385191 G -0.04 (0.04) 0.33 -0.01 (0.05) 0.89 0.06 (0.07) 0.37 0.10 (0.10) 0.30 -0.01 (0.03) 0.83 0.47 
rs1465618 A -0.04 (0.04) 0.28 0.04 (0.05) 0.45 0.003 (0.08) 0.51 -0.03 (0.10) 0.78 -0.01 (0.03) 0.67 0.66 
rs721048 A 0.006 (0.04) 0.88 0.07 (0.05) 0.21 -0.03 (0.09) 0.48 -0.06 (0.13) 0.61 0.02 (0.03) 0.53 0.66 
rs10187424 A 0.05 (0.03) 0.13 -0.05 (0.04) 0.22 0.07 (0.07) 0.31 -0.14 (0.09) 0.10 0.01 (0.02) 0.78 0.07 
rs12621278 A 0.05 (0.08) 0.58 0.19 (0.11) 0.58 - - - - 0.09 (0.07) 0.15 0.3 
rs2292884 G -0.01 (0.04) 0.83 -0.01 (0.05) 0.80 -0.02 (0.08) 0.49 0.02 (0.10) 0.87 -0.01 (0.03) 0.74 0.99 
rs3771570 A -0.05 (0.04) 0.23 0.04 (0.06) 0.51 -0.06 (0.10) 0.41 0.12 (0.13) 0.34 -0.02 (0.03) 0.61 0.41 
rs2660753 T 0.06 (0.05) 0.30 -0.06 (0.06) 0.29 -0.01 (0.08) 0.50 -0.08 (0.15) 0.58 -0.01 (0.04) 0.89 0.47 
rs2055109 C 0.06 (0.04) 0.08 -0.04 (0.05) 0.46 0.08 (0.08) 0.30 -0.06 (0.11) 0.59 0.03 (0.03) 0.27 0.29 
rs7611694 A 0.03 (0.03) 0.38 0.06 (0.05) 0.17 -0.03 (0.07) 0.45 0.12 (0.09) 0.17 0.04 (0.02) 0.12 0.53 
rs10934853 A -0.02 (0.04) 0.59 0.05 (0.05) 0.31 0.10 (0.08) 0.21 -0.16 (0.09) 0.08 0.002 (0.03) 0.93 0.11 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p p-het
1
 
rs10936632 A 0.07 (0.03) 0.03 -0.03 (0.04) 0.43 0.01 (0.07) 0.50 0.03 (0.09) 0.73 0.03 (0.02) 0.18 0.27 
rs1894292 G -0.07 (0.03) 0.05 0.02 (0.04) 0.59 0.04 (0.07) 0.42 -0.03 (0.09) 0.77 -0.02 (0.02) 0.36 0.31 
rs12500426 A -0.002 (0.04) 0.96 0.008 (0.04) 0.85 0.11 (0.07) 0.15 -0.04 (0.09) 0.69 0.01 (0.03) 0.61 0.51 
rs17021918 C -0.02 (0.03) 0.53 0.002 (0.05) 0.97 0.003 (0.07) 0.51 -0.10 (0.10) 0.29 -0.02 (0.03) 0.5 0.8 
rs7679673 C -0.03 (0.03) 0.35 0.04 (0.04) 0.35 -0.07 (0.06) 0.27 0.08 (0.10) 0.42 -0.01 (0.02) 0.71 0.33 
rs2242652 G -0.09 (0.05) 0.06 -0.01 (0.10) 0.89 0.02 (0.11) 0.49 0.11 (0.15) 0.43 -0.05 (0.04) 0.17 0.48 
rs12653946 T 0.01 (0.03) 0.78 -0.03 (0.06) 0.59 -0.17 (0.07) 0.03 -0.14 (0.09) 0.12 -0.03 (0.03) 0.21 0.09 
rs2121875 G -0.03 (0.03) 0.41 0.03 (0.05) 0.45 -0.03 (0.07) 0.47 0.02 (0.09) 0.79 -0.01 (0.03) 0.8 0.7 
rs6869841 A -0.006 (0.04) 0.88 0.02 (0.05) 0.67 0.02 (0.08) 0.49 -0.19 (0.11) 0.08 -0.01 (0.03) 0.83 0.37 
rs130067
1
 G -0.004 (0.04) 0.93 -0.006 (0.06) 0.92 - - - - -0.004 (0.03) 0.9 0.98 
rs3096702
2
 A -0.03 (0.04) 0.44 -0.05 (0.05) 0.31 - - - - -0.04 (0.03) 0.22 0.72 
rs1983891 T -0.001 (0.04) 0.98 0.05 (0.05) 0.24 -0.11 (0.07) 0.15 0.16 (0.09) 0.06 0.02 (0.03) 0.54 0.08 
rs2273669 G 0.03 (0.05) 0.55 0.11 (0.06) 0.06 -0.06 (0.11) 0.44 0.12 (0.13) 0.35 0.05 (0.03) 0.13 0.47 
rs339331 T -0.03 (0.04) 0.47 0.09 (0.05) 0.10 0.10 (0.09) 0.27 0.03 (0.10) 0.78 0.02 (0.03) 0.45 0.26 
rs1933488 A 0.03 (0.03) 0.40 -0.08 (0.05) 0.06 -0.02 (0.07) 0.48 -0.13 (0.09) 0.15 -0.02 (0.02) 0.37 0.14 
rs9364554 T 0.004 (0.03) 0.90 0.05 (0.05) 0.27 -0.01 (0.08) 0.50 -0.10 (0.10) 0.34 0.01 (0.03) 0.71 0.57 
rs12155172 A 0.02 (0.05) 0.72 0.04 (0.05) 0.44 -0.01 (0.09) 0.50 -0.03 (0.11) 0.77 0.02 (0.03) 0.58 0.91 
rs10486567 A 0.08 (0.04) 0.07 -0.06 (0.05) 0.28 0.10 (0.08) 0.21 -0.11 (0.11) 0.28 0.03 (0.03) 0.41 0.09 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p p-het
1
 
rs2928679 T 0.03 (0.03) 0.36 -0.01 (0.04) 0.74 -0.02 (0.06) 0.48 -0.02 (0.09) 0.85 0.007 (0.02) 0.75 0.81 
rs1512268 A 0.01 (0.03) 0.82 -0.01 (0.04) 0.73 0.02 (0.07) 0.48 -0.02 (0.09) 0.77 0.0002 (0.02) 0.99 0.95 
rs11135910 A 0.06 (0.04) 0.15 -0.07 (0.06) 0.28 -0.16 (0.09) 0.09 0.01 (0.12) 0.93 -0.004 (0.03) 0.89 0.09 
rs12543663 C 0.04 (0.04) 0.31 -0.03 (0.05) 0.54 -0.05 (0.07) 0.39 0.10 (0.11) 0.33 0.01 (0.03) 0.68 0.45 
rs10086908 T -0.01 (0.04) 0.82 0.04 (0.05) 0.44 -0.20 (0.08) 0.01 -0.10 (0.10) 0.29 -0.03 (0.03) 0.33 0.04 
rs16901979 A 0.15 (0.08) 0.07 -0.04 (0.10) 0.67 0.11 (0.15) 0.38 0.29 (0.21) 0.16 0.09 (0.06) 0.1 0.35 
rs620861 C 0.05 (0.04) 0.17 -0.01 (0.05) 0.86 0.14 (0.07) 0.07 0.10 (0.09) 0.28 0.05 (0.03) 0.07 0.33 
rs6983267 G 0.04 (0.03) 0.28 0.02 (0.04) 0.67 0.04 (0.07) 0.44 -0.01 (0.09) 0.89 0.03 (0.02) 0.24 0.96 
rs1447295 A 0.07 (0.05) 0.15 0.11 (0.09) 0.21 -0.21 (0.11) 0.09 -0.11 (0.15) 0.45 0.04 (0.04) 0.36 0.08 
rs817826 C 0.04 (0.05) 0.44 0.07 (0.06) 0.26 -0.08 (0.08) 0.28 -0.17 (0.14) 0.21 0.01 (0.04) 0.74 0.21 
rs1571801 A -0.03 (0.04) 0.53 -0.01 (0.05) 0.78 0.14 (0.07) 0.06 0.12 (0.09) 0.18 0.02 (0.03) 0.54 0.12 
rs10993994 T -0.05 (0.04) 0.19 0.02 (0.04) 0.72 -0.05 (0.07) 0.39 0.02 (0.09) 0.84 -0.02 (0.03) 0.38 0.66 
rs3850699 A -0.06 (0.04) 0.12 0.01 (0.05) 0.84 -0.05 (0.08) 0.41 0.09 (0.10) 0.34 -0.03 (0.03) 0.31 0.43 
rs2252004 G 0.01 (0.05) 0.85 0.01 (0.07) 0.94 -0.07 (0.11) 0.40 -0.25 (0.15) 0.09 -0.02 (0.04) 0.63 0.39 
rs4962416 C -0.01 (0.04) 0.80 -0.07 (0.05) 0.15 0.14 (0.08) 0.09 -0.06 (0.11) 0.59 -0.01 (0.03) 0.63 0.13 
rs7127900 A 0.01 (0.04) 0.81 -0.04 (0.05) 0.50 -0.03 (0.08) 0.48 -0.08 (0.11) 0.47 -0.01 (0.03) 0.63 0.83 
rs1938781 C -0.05 (0.04) 0.19 -0.03 (0.05) 0.53 0.07 (0.08) 0.37 -0.14 (0.11) 0.18 -0.04 (0.03) 0.17 0.46 
rs7931342 G -0.04 (0.03) 0.29 0.03 (0.04) 0.49 -0.05 (0.07) 0.40 -0.01 (0.09) 0.92 -0.02 (0.02) 0.54 0.64 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p p-het
1
 
rs10875943 C -0.01 (0.04) 0.87 0.06 (0.05) 0.20 0.02 (0.07) 0.49 0.04 (0.10) 0.65 0.02 (0.03) 0.43 0.73 
rs902774 A -0.001 (0.05) 0.99 -0.01 (0.06) 0.94 0.02 (0.10) 0.49 0.03 (0.11) 0.75 0.004 (0.03) 0.91 0.99 
rs1270884 A 0.01 (0.03) 0.72 0.01 (0.04) 0.90 -0.09 (0.07) 0.20 -0.07 (0.09) 0.39 -0.01 (0.02) 0.69 0.47 
rs9600079 T -0.02 (0.03) 0.51 -0.01 (0.04) 0.83 -0.04 (0.07) 0.44 0.02 (0.09) 0.78 -0.02 (0.03) 0.5 0.95 
rs8008270 G -0.001 (0.04) 0.99 -0.06 (0.06) 0.26 -0.05 (0.08) 0.42 0.12 (0.13) 0.32 -0.02 (0.03) 0.54 0.53 
rs7141529 G 0.03 (0.03) 0.31 -0.03 (0.04) 0.55 0.06 (0.07) 0.34 -0.09 (0.09) 0.30 0.01 (0.02) 0.65 0.39 
rs684232 G 0.02 (0.04) 0.65 -0.004 (0.05) 0.93 -0.16 (0.07) 0.04 -0.03 (0.09) 0.76 -0.02 (0.03) 0.53 0.17 
rs11649743 G -0.04 (0.04) 0.30 0.01 (0.06) 0.90 -0.11 (0.09) 0.22 -0.13 (0.11) 0.23 -0.04 (0.03) 0.15 0.57 
rs4430796 A 0.002 (0.03) 0.95 -0.01 (0.05) 0.78 0.03 (0.07) 0.47 -0.01 (0.09) 0.94 0.0004 (0.02) 0.99 0.97 
rs11650494 A 0.02 (0.06) 0.77 -0.02 (0.08) 0.78 -0.03 (0.11) 0.49 -0.14 (0.16) 0.36 -0.01 (0.04) 0.79 0.81 
rs1859962 G -0.002 (0.03) 0.94 0.03 (0.04) 0.57 -0.06 (0.07) 0.33 0.11 (0.09) 0.21 0.01 (0.02) 0.82 0.46 
rs7241993 G -0.04 (0.04) 0.30 -0.07 (0.05) 0.14 0.08 (0.10) 0.38 0.04 (0.12) 0.72 -0.04 (0.03) 0.18 0.53 
rs8102476 C 0.01 (0.03) 0.68 -0.001 (0.05) 0.98 -0.02 (0.07) 0.49 0.03 (0.09) 0.77 0.01 (0.03) 0.78 0.97 
rs11672691 A -0.02 (0.04) 0.64 0.06 (0.05) 0.31 0.03 (0.08) 0.47 0.02 (0.10) 0.88 0.01 (0.03) 0.7 0.73 
rs2735839 G -0.06 (0.05) 0.20 -0.04 (0.06) 0.57 -0.03 (0.09) 0.48 -0.03 (0.14) 0.81 -0.05 (0.04) 0.16 0.98 
rs103294 C 0.08 (0.04) 0.06 0.08 (0.05) 0.16 -0.13 (0.11) 0.24 - - 0.06 (0.03) 0.05 0.18 
rs2427345 G 0.03 (0.03) 0.39 0.01 (0.08) 0.93 0.03 (0.07) 0.46 -0.18 (0.09) 0.04 0.01 (0.03) 0.76 0.19 
rs6062509 A 0.002 (0.03) 0.95 0.01 (0.05) 0.88 -0.05 (0.07) 0.39 -0.01 (0.10) 0.90 -0.003 (0.03) 0.89 0.92 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p Beta (SE) p p-het
1
 
rs2405942 A -0.02 (0.03) 0.56 0.01 (0.04) 0.78 0.13 (0.06) 0.04 0.06 (0.08) 0.44 0.02 (0.02) 0.45 0.16 
rs5945619 C 0.02 (0.02) 0.33 -0.001 (0.03) 0.98 -0.004 (0.05) 0.50 -0.04 (0.07) 0.53 0.01 (0.02) 0.63 0.78 
rs5919432 A -0.01 (0.03) 0.70 0.02 (0.04) 0.68 0.02 (0.06) 0.47 0.08 (0.08) 0.32 0.01 (0.02) 0.69 0.74 
1data shown for rs115664826 (merged with rs130067) 








RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p 
Beta 
(SE) 





rs1218582 G -0.10 (0.29) 0.72 -0.01 (0.01) 0.25 -0.09 (0.24) 0.84 NA NA -0.01 (0.01) 0.24 0.90 
rs4245739 A -0.06 (0.33) 0.87 -0.01 (0.01) 0.31 -0.07 (0.25) 0.88 NA NA -0.01 (0.01) 0.30 0.96 
rs11902236 A -0.08 (0.31) 0.79 -0.01 (0.01) 0.29 0.19 (0.25) 0.83 NA NA -0.01 (0.01) 0.30 0.72 
rs13385191 G -0.56 (0.36) 0.12 -0.002 (0.01) 0.81 -0.24 (0.26) 0.35 NA NA -0.003 (0.01) 0.76 0.19 
rs1465618 A 0.23 (0.30) 0.45 0.01 (0.01) 0.34 -0.12 (0.28) 0.31 NA NA 0.01 (0.01) 0.34 0.69 
rs721048 A 0.14 (0.34) 0.67 0.01 (0.01) 0.35 -0.72 (0.34) 0.67 NA NA 0.01 (0.01) 0.37 0.10 
rs10187424 A 0.05 (0.29) 0.85 -0.002 (0.01) 0.74 0.30 (0.26) 0.37 NA NA -0.002 (0.01) 0.77 0.48 
rs12621278 A 1.29 (1.11) 0.25 0.01 (0.02) 0.44 - - NA NA 0.01 (0.02) 0.43 0.25 
rs2292884 G 0.05 (0.30) 0.86 -0.01 (0.01) 0.56 0.10 (0.26) 0.54 NA NA -0.01 (0.01) 0.58 0.90 
rs3771570 A -0.59 (0.44) 0.18 -0.01 (0.01) 0.48 0.23 (0.33) 0.71 NA NA -0.01 (0.01) 0.47 0.32 
rs2660753 T 0.01 (0.46) 0.98 -0.01 (0.01) 0.49 0.08 (0.28) 0.15 NA NA -0.01 (0.01) 0.50 0.95 
rs2055109 C 0.29 (0.28) 0.31 0.003 (0.01) 0.69 0.22 (0.25) 0.55 NA NA 0.004 (0.01) 0.65 0.41 
rs7611694 A 0.02 (0.28) 0.94 -0.01 (0.01) 0.34 -0.21 (0.24) 0.70 NA NA -0.01 (0.01) 0.33 0.69 
rs10934853 A -0.10 (0.31) 0.74 -0.01 (0.01) 0.12 -0.25 (0.26) 0.52 NA NA -0.01 (0.01) 0.11 0.65 
rs6763931 T -0.01 (0.28) 0.96 0.002 (0.01) 0.83 -0.17 (0.23) 0.55 NA NA 0.002 (0.01) 0.85 0.74 
rs10936632 A 0.38 (0.28) 0.17 -0.01 (0.01) 0.12 -0.39 (0.24) 0.82 NA NA -0.01 (0.01) 0.12 0.10 
rs1894292 G -0.34 (0.29) 0.24 0.003 (0.01) 0.72 0.18 (0.23) 0.71 NA NA 0.003 (0.01) 0.72 0.37 
rs12500426 A -0.23 (0.29) 0.42 0.01 (0.01) 0.20 0.44 (0.25) 0.08 NA NA 0.01 (0.01) 0.18 0.15 
rs17021918 C 0.0003 (0.29) 1.00 0.01 (0.01) 0.35 0.10 (0.24) 0.52 NA NA 0.01 (0.01) 0.35 0.93 
rs7679673 C -0.26 (0.28) 0.35 -0.01 (0.01) 0.47 -0.09 (0.22) 0.17 NA NA -0.01 (0.01) 0.45 0.61 
rs2242652 G -0.37 (0.35) 0.29 -0.02 (0.02) 0.21 -0.11 (0.37) 0.05 NA NA -0.02 (0.02) 0.19 0.59 
rs12653946 T -0.02 (0.27) 0.95 0.003 (0.01) 0.79 -0.11 (0.25) 0.11 NA NA 0.002 (0.01) 0.81 0.90 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p 
Beta 
(SE) 





rs6869841 A -0.79 (0.42) 0.06 0.016 (0.01) 0.07 0.14 (0.27) 0.49 NA NA 0.02 (0.01) 0.07 0.14 
rs130067
1
 G 0.32 (0.32) 0.32 0.01 (0.01) 0.18 - - NA NA 0.01 (0.01) 0.17 0.34 
rs3096702
2
 A -0.15 (0.30) 0.60 -0.001 (0.01) 0.91 - - NA NA -0.001 (0.01) 0.92 0.62 
rs1983891 T 0.03 (0.30) 0.91 0.01 (0.01) 0.07 0.03 (0.25) 0.16 NA NA 0.01 (0.01) 0.07 1.00 
rs2273669 G -0.01 (0.38) 0.99 0.02 (0.01) 0.02 -0.34 (0.42) 0.40 NA NA 0.02 (0.01) 0.02 0.68 
rs339331 T -0.09 (0.30) 0.78 0.02 (0.01) 0.04 -0.20 (0.31) 0.09 NA NA 0.02 (0.01) 0.04 0.74 
rs1933488 A 0.22 (0.29) 0.45 -0.01 (0.01) 0.21 0.32 (0.24) 0.64 NA NA -0.01 (0.01) 0.23 0.27 
rs9364554 T 0.35 (0.27) 0.19 0.01 (0.01) 0.52 0.08 (0.25) 0.35 NA NA 0.01 (0.01) 0.49 0.42 
rs12155172 A 0.11 (0.36) 0.76 -0.003 (0.01) 0.73 -0.05 (0.29) 0.09 NA NA -0.003 (0.01) 0.73 0.94 
rs10486567 A 0.07 (0.37) 0.84 -0.02 (0.01) 0.08 0.67 (0.26) 0.50 NA NA -0.01 (0.01) 0.10 0.03 
rs6465657 C -0.13 (0.28) 0.64 0.001 (0.01) 0.93 0.18 (0.22) 0.42 NA NA 0.001 (0.01) 0.92 0.65 
rs2928679 T 0.11 (0.26) 0.67 0.002 (0.01) 0.76 -0.05 (0.22) 0.53 NA NA 0.002 (0.01) 0.76 0.89 
rs1512268 A 0.26 (0.28) 0.35 -0.004 (0.01) 0.60 0.003 (0.24) 0.42 NA NA -0.004 (0.01) 0.62 0.63 
rs11135910 A 0.34 (0.34) 0.33 0.002 (0.01) 0.85 -0.08 (0.30) 0.38 NA NA 0.002 (0.01) 0.84 0.60 
rs12543663 C 0.18 (0.28) 0.52 -0.01 (0.01) 0.49 -0.37 (0.26) 0.86 NA NA -0.01 (0.01) 0.47 0.31 
rs10086908 T -0.31 (0.29) 0.29 0.01 (0.01) 0.07 0.02 (0.26) 0.07 NA NA 0.01 (0.01) 0.08 0.54 
rs16901979 A 0.87 (0.51) 0.09 0.01 (0.02) 0.63 0.13 (0.50) 0.69 NA NA 0.01 (0.02) 0.59 0.24 
rs620861 C 0.20 (0.30) 0.52 -0.001 (0.01) 0.88 0.29 (0.26) 0.57 NA NA -0.001 (0.01) 0.92 0.42 
rs6983267 G 0.65 (0.30) 0.03 0.01 (0.01) 0.24 -0.08 (0.24) 0.69 NA NA 0.01 (0.01) 0.22 0.09 
rs1447295 A 0.36 (0.36) 0.31 0.01 (0.01) 0.74 -0.06 (0.41) 0.03 NA NA 0.01 (0.01) 0.72 0.60 
rs817826 C 0.58 (0.39) 0.14 0.01 (0.01) 0.60 0.01 (0.27) 0.42 NA NA 0.01 (0.01) 0.58 0.34 
rs1571801 A -0.59 (0.38) 0.12 0.01 (0.01) 0.52 0.26 (0.24) 0.52 NA NA 0.01 (0.01) 0.52 0.16 
rs10993994 T 0.17 (0.31) 0.58 0.00004 (0.01) 0.99 -0.46 (0.23) 0.35 NA NA -0.0004 (0.01) 0.95 0.11 
rs3850699 A -0.15 (0.30) 0.62 0.01 (0.01) 0.15 0.01 (0.27) 0.52 NA NA 0.01 (0.01) 0.15 0.86 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p 
Beta 
(SE) 





rs4962416 C -0.09 (0.31) 0.77 0.01 (0.01) 0.46 0.47 (0.26) 0.63 NA NA 0.01 (0.01) 0.43 0.18 
rs7127900 A -0.06 (0.34) 0.85 0.001 (0.01) 0.94 -0.29 (0.28) 0.95 NA NA 0.0003 (0.01) 0.97 0.58 
rs1938781 C 0.26 (0.31) 0.40 -0.02 (0.01) 0.06 -0.14 (0.29) 0.77 NA NA -0.02 (0.01) 0.06 0.62 
rs7931342 G -0.14 (0.29) 0.61 0.004 (0.01) 0.57 -0.09 (0.24) 0.76 NA NA 0.004 (0.01) 0.59 0.81 
rs11568818 A -0.48 (0.29) 0.10 0.01 (0.01) 0.13 -0.01 (0.24) 0.39 NA NA 0.01 (0.01) 0.14 0.23 
rs10875943 C -0.23 (0.32) 0.48 0.01 (0.01) 0.31 0.23 (0.24) 0.28 NA NA 0.01 (0.01) 0.30 0.50 
rs902774 A 0.25 (0.36) 0.48 -0.01 (0.01) 0.52 -0.13 (0.33) 0.22 NA NA -0.01 (0.01) 0.53 0.72 
rs1270884 A 0.15 (0.29) 0.59 0.0004 (0.01) 1.00 -0.01 (0.24) 0.40 NA NA 0.0001 (0.01) 0.99 0.87 
rs9600079 T -0.36 (0.30) 0.23 -0.002 (0.01) 0.76 -0.41 (0.26) 0.71 NA NA -0.003 (0.01) 0.70 0.13 
rs8008270 G -0.05 (0.37) 0.90 -0.004 (0.01) 0.66 -0.22 (0.29) 0.79 NA NA -0.004 (0.01) 0.64 0.75 
rs7141529 G 0.58 (0.29) 0.05 0.01 (0.01) 0.40 -0.27 (0.24) 0.61 NA NA 0.01 (0.01) 0.39 0.07 
rs684232 G 0.19 (0.30) 0.52 0.01 (0.01) 0.23 -0.37 (0.25) 0.67 NA NA 0.01 (0.01) 0.24 0.27 
rs11649743 G 0.10 (0.36) 0.79 -0.01 (0.01) 0.56 -0.26 (0.30) 0.37 NA NA -0.01 (0.01) 0.55 0.66 
rs4430796 A -0.08 (0.27) 0.78 0.002 (0.01) 0.79 0.21 (0.24) 0.45 NA NA 0.002 (0.01) 0.78 0.67 
rs11650494 A -0.41 (0.53) 0.44 -0.01 (0.01) 0.60 -0.29 (0.41) 0.39 NA NA -0.01 (0.01) 0.57 0.59 
rs1859962 G 0.17 (0.27) 0.54 -0.01 (0.01) 0.36 -0.06 (0.22) 0.60 NA NA -0.01 (0.01) 0.36 0.79 
rs7241993 G 0.03 (0.31) 0.92 -0.01 (0.01) 0.18 0.27 (0.35) 0.47 NA NA -0.01 (0.01) 0.18 0.73 
rs8102476 C 0.14 (0.28) 0.61 -0.001 (0.01) 0.89 -0.05 (0.25) 0.30 NA NA -0.001 (0.01) 0.89 0.86 
rs11672691 A 0.13 (0.32) 0.68 0.01 (0.01) 0.56 -0.04 (0.27) 0.77 NA NA 0.01 (0.01) 0.55 0.91 
rs2735839 G 0.01 (0.41) 0.99 0.01 (0.01) 0.56 -0.28 (0.29) 0.22 NA NA 0.01 (0.01) 0.58 0.63 
rs103294 C 0.55 (0.40) 0.17 0.01 (0.01) 0.29 -0.19 (0.35) 0.71 NA NA 0.01 (0.01) 0.29 0.34 
rs2427345 G 0.11 (0.28) 0.71 -0.01 (0.01) 0.39 0.29 (0.25) 0.35 NA NA -0.01 (0.01) 0.43 0.43 
rs6062509 A -0.03 (0.29) 0.92 0.01 (0.01) 0.13 -0.25 (0.25) 0.00 NA NA 0.01 (0.01) 0.14 0.57 
rs5759167 G -0.27 (0.28) 0.34 -0.01 (0.01) 0.26 0.32 (0.25) 0.55 NA NA -0.01 (0.01) 0.26 0.28 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 
Beta (SE) p Beta (SE) p Beta (SE) p 
Beta 
(SE) 





rs5945619 C -0.01 (0.20) 0.96 0.001 (0.01) 0.78 0.25 (0.16) 0.73 NA NA 0.002 (0.01) 0.75 0.32 
rs5919432 A -0.27 (0.24) 0.26 0.001 (0.01) 0.83 0.44 (0.23) 0.43 NA NA 0.002 (0.01) 0.81 0.08 
1data shown for rs115664826 (merged with rs130067) 









RAPPER RADIOGEN GenePARE CCI Meta-analysis 





rs1218582 G -0.17 (0.24) 0.48 -0.01 (0.02) 0.67 -0.05 (0.24) 0.84 -0.32 (0.30) 0.28 -0.01 (0.02) 0.56 0.68 
rs4245739 A 0.19 (0.29) 0.52 -0.05 (0.02) 0.03 0.04 (0.25) 0.88 -0.33 (0.35) 0.35 -0.04 (0.02) 0.03 0.70 
rs11902236 A -0.03 (0.26) 0.92 -0.001 (0.02) 0.97 0.06 (0.26) 0.83 -0.44 (0.37) 0.22 -0.002 (0.02) 0.92 0.69 
rs13385191 G -0.12 (0.27) 0.67 -0.01 (0.02) 0.82 0.22 (0.24) 0.35 0.39 (0.35) 0.28 -0.002 (0.02) 0.92 0.51 
rs1465618 A -0.19 (0.28) 0.49 -0.01 (0.02) 0.83 0.27 (0.27) 0.31 -0.45 (0.33) 0.18 -0.01 (0.02) 0.78 0.35 
rs721048 A -0.05 (0.29) 0.88 0.04 (0.02) 0.07 -0.13 (0.30) 0.67 -0.03 (0.44) 0.94 0.04 (0.02) 0.08 0.93 
rs10187424 A 0.21  (0.24) 0.38 -0.02 (0.02) 0.23 -0.23 (0.25) 0.37 -0.48 (0.33) 0.14 -0.03 (0.02) 0.20 0.32 
rs12621278 A -0.19 (0.51) 0.70 0.01 (0.05) 0.91 - - - - 0.004 (0.05) 0.94 0.70 
rs2292884 G 0.49 (0.27) 0.07 -0.05 (0.02) 0.05 -0.16 (0.26) 0.54 0.25 (0.36) 0.49 -0.04 (0.02) 0.07 0.18 
rs3771570 A -0.07 (0.33) 0.84 -0.02 (0.03) 0.59 -0.13 (0.33) 0.71 0.66 (0.42) 0.12 -0.01 (0.03) 0.63 0.44 
rs2660753 T 0.23 (0.38) 0.55 0.03 (0.03) 0.30 -0.42 (0.29) 0.15 0.48 (0.46) 0.31 0.03 (0.03) 0.32 0.32 
rs2055109 C 0.05 (0.26) 0.86 0.01 (0.02) 0.67 0.15 (0.26) 0.55 -0.47 (0.43) 0.27 0.01 (0.02) 0.66 0.67 
rs7611694 A 0.28 (0.25) 0.27 0.03 (0.02) 0.22 -0.09 (0.24) 0.70 -0.16 (0.30) 0.59 0.03 (0.02) 0.21 0.66 
rs10934853 A -0.07 (0.27) 0.81 0.04 (0.02) 0.12 0.16 (0.26) 0.52 -0.17 (0.31) 0.59 0.04 (0.02) 0.12 0.85 
rs6763931 T 0.25 (0.24) 0.31 0.003 (0.02) 0.87 -0.14 (0.23) 0.55 -0.14 (0.33) 0.68 0.003 (0.02) 0.87 0.67 
rs10936632 A 0.18 (0.23) 0.43 0.004 (0.02) 0.82 0.05 (0.23) 0.82 0.16 (0.31) 0.61 0.01 (0.02) 0.72 0.84 
rs1894292 G -0.45 (0.25) 0.07 0.01 (0.02) 0.65 0.09 (0.23) 0.71 -0.34 (0.31) 0.27 0.01 (0.02) 0.80 0.19 
rs12500426 A 0.06 (0.25) 0.80 0.01 (0.02) 0.55 0.43 (0.25) 0.08 0.06 (0.30) 0.84 0.02 (0.02) 0.44 0.42 
rs17021918 C -0.11 (0.24) 0.65 -0.02 (0.02) 0.46 0.15 (0.23) 0.52 -0.49 (0.33) 0.15 -0.02 (0.02) 0.42 0.46 
rs7679673 C -0.20 (0.24) 0.42 0.01 (0.02) 0.77 -0.31 (0.22) 0.17 0.05 (0.33) 0.89 0.002 (0.02) 0.92 0.45 
rs2242652 G -0.63 (0.30) 0.04 0.01 (0.04) 0.88 0.78 (0.41) 0.05 -0.06 (0.51) 0.91 0.001 (0.04) 0.97 0.05 
rs12653946 T -0.05 (0.23) 0.82 0.01 (0.03) 0.86 -0.40 (0.25) 0.11 -0.54 (0.33) 0.09 -0.004 (0.03) 0.89 0.15 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 





rs6869841 A -0.40 (0.31) 0.20 -0.01 (0.02) 0.77 -0.19 (0.28) 0.49 -1.23 (0.51) 0.01 -0.01 (0.03) 0.57 0.05 
rs130067
1
 G -0.80 (0.36) 0.03 0.01 (0.03) 0.81 - - - - 0.002 (0.03) 0.94 0.02 
rs3096702
2
 A -0.17 (0.25) 0.48 -0.01 (0.02) 0.846 - - - - -0.01 (0.02) 0.62 0.52 
rs1983891 T -0.15 (0.26) 0.56 0.02 (0.02) 0.38 -0.35 (0.25) 0.16 0.36 (0.29) 0.23 0.02 (0.02) 0.43 0.27 
rs2273669 G 0.14 (0.32) 0.66 0.04 (0.03) 0.15 -0.35 (0.42) 0.40 -0.72 (0.52) 0.14 0.04 (0.03) 0.18 0.38 
rs339331 T 0.07 (0.27) 0.80 0.02 (0.02) 0.54 -0.52 (0.31) 0.09 0.62 (0.36) 0.07 0.02 (0.02) 0.54 0.11 
rs1933488 A 0.34 (0.25) 0.17 -0.02 (0.02) 0.46 0.11 (0.23) 0.64 -0.40 (0.31) 0.19 -0.01 (0.02) 0.51 0.27 
rs9364554 T 0.16 (0.24) 0.49 0.01 (0.02) 0.52 -0.25 (0.26) 0.35 0.13 (0.35) 0.72 0.01 (0.02) 0.52 0.69 
rs12155172 A -0.16 (0.33) 0.63 0.03 (0.02) 0.28 -0.49 (0.30) 0.09 0.17 (0.36) 0.65 0.02 (0.02) 0.35 0.33 
rs10486567 A 0.62 (0.29) 0.03 -0.07 (0.02) 0.01 0.18 (0.26) 0.50 0.31 (0.34) 0.37 -0.06 (0.02) 0.02 0.06 
rs6465657 C -0.15 (0.24) 0.53 0.001 (0.02) 0.96 0.18 (0.23) 0.42 -0.60 (0.35) 0.08 -0.001 (0.02) 0.97 0.25 
rs2928679 T 0.19 (0.22) 0.39 -0.02 (0.02) 0.24 0.14 (0.22) 0.53 -0.002 (0.30) 1.00 -0.02 (0.02) 0.31 0.70 
rs1512268 A -0.47 (0.25) 0.06 -0.02 (0.02) 0.42 0.19 (0.24) 0.42 0.44 (0.31) 0.15 -0.02 (0.02) 0.43 0.11 
rs11135910 A 0.27 (0.29) 0.35 0.001 (0.03) 0.96 -0.28 (0.32) 0.38 0.10 (0.40) 0.82 0.002 (0.03) 0.94 0.64 
rs12543663 C 0.32 (0.24) 0.18 0.01 (0.02) 0.63 0.04 (0.25) 0.86 0.05 (0.37) 0.89 0.01 (0.02) 0.53 0.65 
rs10086908 T -0.25 (0.25) 0.32 -0.04 (0.02) 0.08 -0.46 (0.26) 0.07 -0.35 (0.33) 0.29 -0.05 (0.02) 0.04 0.24 
rs16901979 A 0.12 (0.53) 0.82 -0.03 (0.04) 0.51 0.20 (0.50) 0.69 0.96 (0.63) 0.14 -0.02 (0.04) 0.62 0.43 
rs620861 C 0.02 (0.26) 0.93 0.02 (0.02) 0.36 0.14 (0.25) 0.57 -0.03 (0.33) 0.92 0.02 (0.02) 0.34 0.97 
rs6983267 G 0.34 (0.24) 0.16 -0.004 (0.02) 0.85 0.09 (0.24) 0.69 -0.13(0.31) 0.66 -0.001 (0.02) 0.95 0.51 
rs1447295 A 0.18 (0.32) 0.58 0.03 (0.04) 0.47 -0.96 (0.46) 0.03 0.17 (0.51) 0.74 0.03 (0.04) 0.53 0.19 
rs817826 C -0.35 (0.40) 0.38 -0.003 (0.03) 0.91 -0.21 (0.26) 0.42 -0.30 (0.52) 0.55 -0.01 (0.03) 0.77 0.65 
rs1571801 A 0.15 (0.28) 0.60 -0.03 (0.02) 0.23 0.16 (0.25) 0.52 0.39 (0.30) 0.19 -0.02 (0.02) 0.33 0.41 
rs10993994 T -0.03 (0.27) 0.92 0.02 (0.02) 0.46 -0.21 (0.23) 0.35 0.02 (0.31) 0.95 0.01 (0.02) 0.51 0.80 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 





rs2252004 G 0.27 (0.45) 0.55 0.02 (0.03) 0.48 -0.70 (0.38) 0.06 -0.29 (0.57) 0.59 0.02 (0.03) 0.58 0.23 
rs4962416 C -0.86 (0.31) 0.01 -0.04  (0.02) 0.05 0.13 (0.26) 0.63 0.21 (0.37) 0.58 -0.04 (0.02) 0.04 0.06 
rs7127900 A -0.16 (0.29) 0.58 -0.01 (0.03) 0.77 -0.02 (0.27) 0.95 -0.17 (0.41) 0.68 -0.01 (0.03) 0.71 0.93 
rs1938781 C -0.01 (0.29) 0.97 0.0002 (0.02) 0.99 0.08 (0.28) 0.77 -0.45 (0.40) 0.25 -0.001 (0.02) 0.97 0.72 
rs7931342 G -0.05 (0.24) 0.85 -0.01 (0.02) 0.48 0.08 (0.24) 0.76 -0.19 (0.32) 0.56 -0.01 (0.02) 0.47 0.93 
rs11568818 A -0.14 (0.25) 0.57 -0.002 (0.02) 0.92 -0.21 (0.24) 0.39 0.03 (0.34) 0.92 -0.004 (0.02) 0.84 0.79 
rs10875943 C 0.17 (0.26) 0.50 -0.01 (0.02) 0.70 -0.27 (0.25) 0.28 0.53 (0.33) 0.10 -0.01 (0.02) 0.76 0.23 
rs902774 A -0.27 (0.36) 0.46 -0.001 (0.03) 0.97 0.40 (0.32) 0.22 -0.21 (0.42) 0.62 -0.001 (0.03) 0.99 0.51 
rs1270884 A 0.42 (0.25) 0.09 0.02 (0.02) 0.28 -0.20 (0.24) 0.40 -0.21 (0.30) 0.47 0.02 (0.02) 0.27 0.25 
rs9600079 T -0.09 (0.25) 0.72 -0.01 (0.02) 0.63 -0.09 (0.25) 0.71 -0.57 (0.32) 0.07 -0.01 (0.02) 0.52 0.36 
rs8008270 G -0.21 (0.30) 0.49 -0.02 (0.03) 0.37 -0.08 (0.29) 0.79 0.27 (0.44) 0.53 -0.02 (0.03) 0.35 0.84 
rs7141529 G 0.17 (0.23) 0.46 0.002 (0.02) 0.94 0.12 (0.24) 0.61 -0.08 (0.30) 0.80 0.003 (0.02) 0.87 0.84 
rs684232 G 0.09 (0.25) 0.71 -0.03 (0.02) 0.19 -0.10 (0.24) 0.67 -0.08 (0.31) 0.80 -0.03 (0.02) 0.19 0.95 
rs11649743 G -0.08 (0.31) 0.81 0.04 (0.03) 0.11 0.30 (0.33) 0.37 -0.30 (0.36) 0.41 0.04 (0.03) 0.11 0.65 
rs4430796 A 0.33 (0.24) 0.16 -0.05 (0.02) 0.03 0.18 (0.24) 0.45 0.29 (0.31) 0.34 -0.04 (0.02) 0.06 0.20 
rs11650494 A -0.10 (0.40) 0.80 0.01 (0.04) 0.80 -0.35 (0.42) 0.39 -0.43 (0.56) 0.42 0.004 (0.04) 0.92 0.70 
rs1859962 G 0.14 (0.24) 0.56 0.02 (0.02) 0.30 -0.12 (0.22) 0.60 0.14 (0.32) 0.67 0.02 (0.02) 0.30 0.86 
rs7241993 G -0.43 (0.25) 0.08 0.02 (0.02) 0.33 0.25 (0.35) 0.47 0.02 (0.41) 0.97 0.02 (0.02) 0.39 0.29 
rs8102476 C 0.30 (0.25) 0.23 -0.01 (0.02) 0.79 -0.25 (0.25) 0.30 0.29 (0.32) 0.36 -0.004 (0.02) 0.85 0.34 
rs11672691 A -0.14 (0.29) 0.65 -0.02 (0.02) 0.48 0.08 (0.27) 0.77 -0.08 (0.35) 0.82 -0.02 (0.03) 0.46 0.96 
rs2735839 G 0.16 (0.40) 0.69 0.004 (0.03) 0.89 -0.38 (0.30) 0.22 0.92 (0.53) 0.06 0.004 (0.03) 0.89 0.19 
rs103294 C -0.21 (0.27) 0.45 0.02 (0.03) 0.53 -0.13 (0.36) 0.71 - - 0.01 (0.03) 0.60 0.66 
rs2427345 G 0.15 (0.25) 0.55 0.01 (0.04) 0.80 0.23 (0.24) 0.35 -0.36 (0.31) 0.23 0.01 (0.03) 0.74 0.46 
rs6062509 A -0.17 (0.24) 0.48 -0.01 (0.02) 0.73 -0.73 (0.26) 0.004 0.02 (0.34) 0.95 -0.01 (0.02) 0.52 0.04 






RAPPER RADIOGEN GenePARE CCI Meta-analysis 





rs2405942 A -0.05 (0.22) 0.83 -0.01 (0.02) 0.53 0.50 (0.23) 0.02 -0.13 (0.25) 0.60 -0.01 (0.02) 0.61 0.17 
rs5945619 C 0.05 (0.17) 0.77 0.01 (0.01) 0.50 -0.06 (0.16) 0.73 -0.10 (0.25) 0.69 0.01 (0.01) 0.53 0.94 
rs5919432 A -0.06 (0.23) 0.78 0.01 (0.02) 0.58 0.16 (0.20) 0.43 0.29 (0.31) 0.33 0.01 (0.02) 0.52 0.70 
1data shown for rs115664826 (merged with rs130067) 
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rs1218582 G 0.35 (0.18) 0.05 -0.01 (0.02) 0.56 -0.34 (0.23) 0.14 -0.53 (0.29) 0.06 -0.01 (0.02) 0.53 0.02 
rs4245739 A 0.01 (0.21) 0.95 0.05 (0.02) 0.03 -0.21 (0.24) 0.38 0.07 (0.34) 0.83 0.04 (0.02) 0.04 0.76 
rs11902236 A 0.34 (0.19) 0.08 -0.02 (0.02) 0.25 -0.08 (0.24) 0.73 0.27 (0.32) 0.40 -0.02 (0.02) 0.35 0.22 
rs13385191 G -0.07 (0.20) 0.71 -0.02 (0.02) 0.49 0.19 (0.23) 0.41 0.26 (0.32) 0.42 -0.01 (0.02) 0.55 0.66 
rs1465618 A -0.33 (0.22) 0.14 0.02 (0.02) 0.30 -0.28 (0.28) 0.30 0.79 (0.37) 0.02 0.02 (0.02) 0.35 0.05 
rs721048 A 0.11 (0.21) 0.62 -0.03 (0.02) 0.22 -0.15 (0.29) 0.61 -0.52 (0.42) 0.20 -0.03 (0.02) 0.20 0.59 
rs10187424 A 0.20 (0.19) 0.28 0.01 (0.02) 0.66 -0.07 (0.23) 0.76 0.03 (0.29) 0.92 0.01 (0.02) 0.60 0.76 
rs12621278 A 0.06 (0.46) 0.90 0.11 (0.05) 0.03 - - - - 0.11 (0.05) 0.03 0.91 
rs2292884 G -0.26 (0.20) 0.20 0.02 (0.02) 0.30 0.47 (0.25) 0.06 -0.23 (0.34) 0.50 0.02 (0.02) 0.31 0.12 
rs3771570 A -0.18 (0.24) 0.46 0.01 (0.03) 0.58 -0.12 (0.33) 0.71 0.34 (0.39) 0.39 0.01 (0.03) 0.63 0.69 
rs2660753 T 0.30 (0.27) 0.25 0.02 (0.03) 0.52 0.27 (0.26) 0.31 -0.43 (0.50) 0.38 0.02 (0.03) 0.42 0.41 
rs2055109 C 0.06 (0.19) 0.75 -0.02 (0.02) 0.36 0.09 (0.24) 0.71 -0.04 (0.36) 0.91 -0.02 (0.02) 0.40 0.95 
rs7611694 A -0.03 (0.18) 0.86 0.01 (0.02) 0.47 -0.09 (0.22) 0.70 0.80 (0.31) 0.01 0.02 (0.02) 0.41 0.09 
rs10934853 A 0.20 (0.19) 0.30 0.03 (0.02) 0.14 0.41 (0.24) 0.09 -0.28 (0.29) 0.33 0.04 (0.02) 0.10 0.23 
rs6763931 T 0.24 (0.18) 0.18 -0.02 (0.02) 0.25 -0.18 (0.22) 0.41 -0.35 (0.31) 0.26 -0.02 (0.02) 0.26 0.29 
rs10936632 A 0.04 (0.17) 0.83 -0.006 (0.02) 0.78 0.09 (0.22) 0.68 0.06 (0.28) 0.84 -0.004 (0.02) 0.84 0.96 
rs1894292 G -0.05 (0.19) 0.79 -0.02 (0.02) 0.32 -0.12 (0.22) 0.58 0.01 (0.28) 0.98 -0.02(0.02) 0.29 0.97 
rs12500426 A 0.06 (0.19) 0.77 -0.03 (0.02) 0.09 -0.03 (0.23) 0.89 -0.43 (0.28) 0.12 -0.03 (0.02) 0.08 0.52 
rs17021918 C -0.19 (0.18) 0.28 -0.004 (0.02) 0.84 -0.35 (0.23) 0.12 -0.22 (0.31) 0.47 -0.01 (0.02) 0.61 0.27 
rs7679673 C 0.13 (0.19) 0.49 0.01  (0.02) 0.52 0.23 (0.21) 0.27 0.14 (0.31) 0.66 0.02 (0.02) 0.40 0.66 
rs2242652 G 0.17 (0.25) 0.49 0.06 (0.04) 0.13 -0.70 (0.34) 0.04 0.33 (0.48) 0.48 0.06 (0.04) 0.16 0.14 
rs12653946 T 0.07 (0.17) 0.68 -0.02 (0.03) 0.42 -0.15 (0.23) 0.51 -0.18 (0.29) 0.52 -0.02 (0.03) 0.39 0.82 
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rs6869841 A 0.01 (0.21) 0.96 -0.01 (0.02) 0.58 -0.17 (0.27) 0.53 0.14 (0.36) 0.69 -0.01 (0.02) 0.57 0.91 
rs130067
1
 G -0.08 (0.22) 0.71 -0.01 (0.03) 0.76 - - - - -0.01 (0.03) 0.73 0.74 
rs3096702
2
 A 0.02 (0.19) 0.93 0.003 (0.02) 0.90 - - - - 0.003 (0.02) 0.88 0.93 
rs1983891 T -0.05 (0.20) 0.82 -0.04 (0.02) 0.03 -0.34 (0.25) 0.15 0.35 (0.27) 0.18 -0.04 (0.02) 0.03 0.29 
rs2273669 G 0.13 (0.24) 0.57 -0.01 (0.03) 0.77 0.77 (0.34) 0.02 0.19 (0.41) 0.65 -0.001 (0.03) 0.99 0.12 
rs339331 T -0.19 (0.19) 0.32 0.004 (0.02) 0.86 0.20 (0.30) 0.52 -0.10 (0.29) 0.74 0.002 (0.02) 0.93 0.67 
rs1933488 A 0.12 (0.18) 0.53 0.01 (0.02) 0.71 -0.06 (0.22) 0.77 -0.26 (0.28) 0.36 0.01 (0.02) 0.73 0.71 
rs9364554 T -0.03 (0.19) 0.88 -0.004 (0.02) 0.84 -0.02 (0.25) 0.93 -0.35 (0.32) 0.28 -0.01 (0.02) 0.77 0.77 
rs12155172 A -0.05 (0.24) 0.84 -0.03 (0.02) 0.25 0.11 (0.28) 0.70 0.09 (0.35) 0.81 -0.03 (0.02) 0.27 0.95 
rs10486567 A 0.40 (0.22) 0.07 -0.04 (0.02) 0.14 -0.31 (0.26) 0.23 -0.42 (0.35) 0.22 -0.03 (0.02) 0.15 0.10 
rs6465657 C -0.05 (0.18) 0.77 -0.03 (0.02) 0.17 0.23 (0.21) 0.28 0.32 (0.31) 0.30 -0.02 (0.02) 0.22 0.44 
rs2928679 T 0.06 (0.17) 0.73 -0.01 (0.02) 0.44 0.12 (0.21) 0.58 0.05 (0.28) 0.87 -0.01 (0.02) 0.51 0.90 
rs1512268 A 0.09 (0.18) 0.63 0.01 (0.02) 0.67 0.31 (0.22) 0.16 0.01 (0.27) 0.97 0.01 (0.02) 0.56 0.58 
rs11135910 A 0.14 (0.23) 0.52 -0.04 (0.03) 0.15 -0.03 (0.28) 0.92 -0.16 (0.37) 0.67 -0.04 (0.03) 0.17 0.86 
rs12543663 C -0.10 (0.19) 0.62 -0.01 (0.02) 0.60 -0.32 (0.25) 0.18 0.48 (0.36) 0.18 -0.01 (0.02) 0.54 0.30 
rs10086908 T 0.25 (0.21) 0.24 0.03 (0.02) 0.23 -0.61 (0.25) 0.01 -0.12 (0.30) 0.69 0.02 (0.02) 0.28 0.05 
rs16901979 A 0.64 (0.37) 0.08 0.03 (0.04) 0.47 0.02 (0.49) 0.97 0.67 (0.63) 0.30 0.04 (0.04) 0.33 0.30 
rs620861 C 0.01 (0.19) 0.96 -0.02 (0.02) 0.38 0.29 (0.24) 0.23 0.27 (0.28) 0.34 -0.01 (0.02) 0.49 0.45 
rs6983267 G -0.01 (0.17) 0.95 0.01 (0.02) 0.76 -0.01 (0.22) 0.97 -0.02 (0.28) 0.94 0.01 (0.02) 0.78 0.99 
rs1447295 A 0.29 (0.23) 0.22 0.04 (0.04) 0.30 -0.36 (0.42) 0.38 -0.65 (0.54) 0.20 0.04 (0.04) 0.29 0.30 
rs817826 C -0.002 (0.29) 0.99 0.03 (0.03) 0.28 0.02 (0.25) 0.93 -0.73 (0.52) 0.13 0.03 (0.03) 0.31 0.54 
rs1571801 A -0.20 (0.23) 0.37 -0.03 (0.02) 0.20 0.09 (0.24) 0.71 0.23 (0.28) 0.41 -0.03 (0.02) 0.21 0.64 
rs10993994 T -0.29 (0.2) 0.15 -0.01 (0.02) 0.72 0.32 (0.22) 0.15 -0.01 (0.28) 0.98 -0.01 (0.02) 0.71 0.25 
rs3850699 A -0.32 (0.19) 0.08 -0.01 (0.02) 0.84 -0.12 (0.25) 0.62 0.05 (0.32) 0.88 -0.01 (0.02) 0.66 0.38 
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rs4962416 C 0.30 (0.19) 0.11 -0.002 (0.02) 0.92 0.19 (0.25) 0.44 -0.13 (0.34) 0.71 0.002 (0.02) 0.90 0.35 
rs7127900 A 0.35 (0.20) 0.09 -0.02 (0.02) 0.39 0.12 (0.26) 0.64 0.11 (0.34) 0.74 -0.01 (0.02) 0.56 0.30 
rs1938781 C -0.23 (0.22) 0.31 -0.01 (0.02) 0.61 -0.12 (0.28) 0.67 -0.09 (0.34) 0.79 -0.02 (0.02) 0.50 0.77 
rs7931342 G -0.21 (0.18) 0.26 0.02 (0.02) 0.25 0.12 (0.23) 0.59 0.05 (0.30) 0.86 0.02 (0.02) 0.28 0.62 
rs11568818 A 0.23 (0.19) 0.22 0.04 (0.02) 0.03 -0.23 (0.24) 0.34 -0.12 (0.31) 0.69 0.04 (0.02) 0.03 0.46 
rs10875943 C 0.37 (0.19) 0.06 0.04 (0.02) 0.06 0.32 (0.23) 0.16 -0.41 (0.32) 0.19 0.04 (0.02) 0.03 0.10 
rs902774 A 0.15 (0.24) 0.52 0.004 (0.03) 0.88 0.35 (0.29) 0.24 0.30 (0.33) 0.37 0.01 (0.03) 0.68 0.48 
rs1270884 A -0.05 (0.19) 0.80 -0.02 (0.02) 0.29 -0.32 (0.23) 0.16 -0.16 (0.28) 0.58 -0.02 (0.02) 0.22 0.58 
rs9600079 T -0.04 (0.18) 0.83 -0.02 (0.02) 0.44 0.06 (0.23) 0.81 0.73 (0.30) 0.01 -0.01 (0.02) 0.54 0.11 
rs8008270 G -0.07 (0.23) 0.76 0.01 (0.03) 0.68 -0.11 (0.27) 0.69 -0.09 (0.38) 0.81 0.01 (0.03) 0.74 0.94 
rs7141529 G 0.20 (0.18) 0.26 0.01 (0.02) 0.70 -0.18 (0.22) 0.41 -0.31 (0.29) 0.27 0.01 (0.02) 0.72 0.36 
rs684232 G -0.03 (0.19) 0.86 -0.01 (0.02) 0.80 -0.14 (0.23) 0.54 0.10 (0.28) 0.72 -0.01 (0.02) 0.76 0.92 
rs11649743 G -0.04 (0.22) 0.87 -0.01 (0.02) 0.82 0.06 (0.29) 0.83 0.05 (0.34) 0.89 -0.01 (0.02) 0.83 0.99 
rs4430796 A -0.10 (0.17) 0.56 0.02 (0.02) 0.30 -0.21 (0.23) 0.37 0.07 (0.28) 0.81 0.02 (0.02) 0.38 0.69 
rs11650494 A 0.19 (0.28) 0.49 0.01 (0.04) 0.84 0.34 (0.34) 0.32 -0.32 (0.52) 0.52 0.01 (0.04) 0.73 0.62 
rs1859962 G -0.08 (0.17) 0.66 0.02 (0.02) 0.35 -0.03 (0.22) 0.88 0.06 (0.29) 0.84 0.02 (0.02) 0.38 0.95 
rs7241993 G 0.04 (0.20) 0.85 -0.04 (0.02) 0.10 0.19 (0.34) 0.58 0.06 (0.37) 0.88 -0.03 (0.02) 0.12 0.89 
rs8102476 C 0.09 (0.18) 0.63 -0.01 (0.02) 0.55 0.03 (0.24) 0.88 0.02 (0.29) 0.96 -0.01 (0.02) 0.61 0.95 
rs11672691 A -0.26 (0.22) 0.24 0.04 (0.02) 0.10 0.20 (0.25) 0.43 -0.07 (0.31) 0.82 0.04 (0.02) 0.12 0.50 
rs2735839 G -0.27 (0.24) 0.26 -0.06 (0.03) 0.02 0.33 (0.31) 0.28 -0.33 (0.41) 0.43 -0.06 (0.03) 0.02 0.43 
rs103294 C 0.27 (0.23) 0.25 -0.01 (0.02) 0.64 0.40 (0.39) 0.29 - - -0.01 (0.02) 0.77 0.28 
rs2427345 G 0.17 (0.18) 0.35 -0.04 (0.03) 0.26 -0.44 (0.23) 0.06 -0.39 (0.29) 0.16 -0.04 (0.03) 0.18 0.12 
rs6062509 A 0.04 (0.18) 0.84 0.01 (0.02) 0.80 -0.33 (0.24) 0.17 -0.16 (0.30) 0.59 0.002 (0.02) 0.91 0.51 
rs5759167 G -0.002 (0.18) 0.99 0.02 (0.02) 0.36 -0.11 (0.23) 0.64 0.18 (0.29) 0.53 0.02 (0.02) 0.37 0.89 
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rs5945619 C 0.12 (0.13) 0.35 -0.01 (0.01) 0.47 -0.07 (0.16) 0.67 -0.03 (0.22) 0.89 -0.01 (0.01) 0.50 0.77 
rs5919432 A 0.06 (0.18) 0.74 0.01 (0.02) 0.46 0.02 (0.19) 0.91 0.30 (0.27) 0.26 0.01 (0.02) 0.39 0.76 
1data shown for rs115664826 (merged with rs130067) 
2data shown for rs114376585 (merged with rs3096702) for RAPPER only 
 
 
 
